Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 2Other hematologic neoplasm 1Lymphoid 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 2Recurrence 1

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Salvage Therapy × Genitourinary × Clear all
NCT01558427 2023-09-05

Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer

University Hospital, Ghent

Phase 2 Completed
62 enrolled
Genitourinary

Prostatic Neoplasms

NCT01531205 2014-11-05

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
Genitourinary

Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡